Global Sarcoma Therapeutics Market 2019-2023
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 114 Pages
The advent of regenerative medicine to drive growth in the market. One of the most advanced and extensively researched treatment methods is regenerative medicines, including gene therapy. In gene therapy, the mutated gene is taken from the patient and is modified genetically in laboratory and administered back into the patient. Technavio's analysts have predicted that the sarcoma therapeutics market will register a CAGR of more than 8% by 2023.
The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. The launch of novel drugs is expected to be one of the major growth drivers in the market.
The cost of therapeutics is usually high as most of the drugs that are currently approved in the market are large molecules. These drugs are expensive due to the complex manufacturing process of biologicals and high R&D costs.
For the detailed list of factors that will drive and challenge the growth of the sarcoma therapeutics market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Bayer and Eisai the competitive environment is quite intense. Factors such as the advent of regenerative medicine and the launch of novel drugs, will provide considerable growth opportunities to sarcoma therapeutics manufactures. Bayer, Eisai, Eli Lilly, Johnson & Johnson, and Novartis are some of the major companies covered in this report.